Novo Nordisk A/S – Share buyback program

BagsværdDenmark, 25 April 2022 – On February 2, 2022, Novo Nordisk launched a share buyback program in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and of the Council of April 16, 2014 (MAR) and Delegated Regulation (EU) 2016/1052 of March 8, 2016 (the “safe harbor rules”). This program is part of the global share buyback program of up to DKK 22 billion to be executed over a period of 12 months from 2 February 2022.

Under the program initiated on February 2, 2022, Novo Nordisk will buy back B shares for an amount of up to DKK 4.4 billion over the period from February 2, 2022 to May 2, 2022.

Since the April 11, 2022 announcement, the following transactions have taken place:

Number of
Buying price
value, DKK
Accumulated, last announcement 4,962,250 3,486,567,177
April 11, 2022 90,000 825.33 74,279,900
April 12, 2022 90,000 812.32 73 108 763
April 13, 2022 90,000 808.58 72,772,526
April 19, 2022 88,000 785.16 69,094,325
April 20, 2022 90,000 790.48 71,142,769
April 21, 2022 95,000 784.98 74,573,405
April 22, 2022 90,000 771.32 69,418,845
Accumulated under the program 5,595,250 3,990,957,709

Details of each operation carried out under the share buyback program are published on

Transactions related to Novo Nordisk’s incentive programs resulted in a net transfer from Novo Nordisk of 16,116 B shares during the period from April 11, 2022 to April 22, 2022. The shares of these transactions did not part of the Safe Harbor buyback program.

With the transactions described above, Novo Nordisk holds a total of 37,365,302 B shares of DKK 0.20 as treasury shares, corresponding to 1.6% of the share capital. The total amount of A and B shares of the company is 2,310,000,000, including treasury shares.

Novo Nordisk plans to repurchase B shares for an amount of up to DKK 22 billion over a 12-month period starting February 2, 2022. As of April 22, 2022, Novo Nordisk has since February 2, 2022 repurchased a total of 5 595,250 B shares at an average price of DKK 713.28 per B share equal to a transaction value of DKK 3,990,957,709.

Novo Nordisk is a leading global healthcare company, founded in 1923 and based in Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do this by paving the way for scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 47,800 people in 80 countries and markets its products in approximately 170 countries. Novo Nordisk B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Twitter, LinkedInand Youtube.

More information

  • CA220425_Share_repurchase